Navigating the fast-paced cell and gene therapy landscape? Stay ahead of the curve with our curated news on viral vectors in cell & gene therapy July 2024 edition. Read here: Virica's Industry Insights- July Edition.
Invest Ottawa announces Virica’s graduation from its flagship program following significant growth, increased revenue, team expansion, creating numerous jobs, and securing critical funding. As Virica transitions to the IO ScaleUp program, its aim is to expand services, enter new markets, and continue helping life-saving cell and gene therapies scale. Read Full Article: LINK HERE
On June 24, 2024, Yasir Naqvi, Parliamentary Secretary to the Minister of Health and Member of Parliament for Ottawa Centre, on behalf of the Honourable Filomena Tassi, Minister responsible for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), announced a $1.5 million repayable investment to support the expansion of Virica's new facility [...]
Virica has been selected as a project lead for one of NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals planned projects, which aim to address key opportunities for innovation in biopharmaceutical manufacturing. NIIMBL is a public-private partnership whose mission is to accelerate biopharmaceutical manufacturing. Virica, with support from NIIMBL members AstraZeneca and Sartorius Stedim Biotech, aims to increase [...]
Navigating the fast-paced cell and gene therapy landscape? Stay ahead of the curve with our curated news on viral vectors in cell & gene therapy April 2024 edition. Read here: Virica's Industry Insights- April Edition.
Navigating the fast-paced cell and gene therapy landscape? Stay ahead of the curve with our curated news on viral vectors in cell & gene therapy January edition. Read here: Virica's Industry Insights- January Edition
Our own Ella Korets-Smith, Chief Strategy Officer and co-founder of Virica Biotech, has been featured in the Ottawa Business Journal for her impactful role in advancing breakthrough biotechnology to “democratize gene therapy.” Virica’s vision is to make gene therapies accessible and affordable. Ella shares her entrepreneurial journey building Virica from an idea to a thriving [...]
Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vectors and cell and gene therapies, announces a significant expansion of bioprocessing services through a strategic partnership with Carleton University in a PRESS RELEASE. "This multi-year, multi-million-dollar research and infrastructure partnership will help drive innovation and talent development in the Ottawa [...]
Cell & gene therapy (C>) is complex, expensive and lacks standardization. How do you effectively evaluate and make informed decisions to identify a winning viral vector production strategy to improve the accessibility & affordability of C>? We are thrilled to announce our Fast Facts video with Cell & Gene Insights, where our expert Andrea Vervoort, [...]
Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vectors, as well as cell and gene therapies, announced today the expansion of their sales team along with a full presentation calendar in a PRESS RELEASE. Azra Benson, a veteran stem cell scientist with extensive commercial experience in the cell and [...]
